Itaborahy, Matheus F.
Feng, Isadora Z. L. F.
Vieira-Machado, Uri F.
da Silveira, Izabela B.
Valverde, Thalita M.
Costa, Guilherme M. J.
Guimarães, Jennifer D. S.
Laet-Souza, Daniela
Malamut, Carlos
Martins, M. Alessandra F.
Marques, Júlia M.
Rezende-Ribeiro, Julia
Gorshkov, Vladimir
Kjeldsen, Frank
Favalessa, Maria Eduarda S.
Acipreste, Izabella F.
Verano-Braga, Thiago
Carvalho, Hernandes F. https://orcid.org/0000-0002-3080-9447
Oliveira, André G.
Dias, Marlon Lemos https://orcid.org/0000-0001-9354-7280
Goes, Alfredo M.
Ehrlich, Barbara E.
Leite, M. Fatima https://orcid.org/0000-0001-9709-8865
Funding for this research was provided by:
Instituto Nacional de Ciência e Tecnologia de Nanobiofarmacêutica
Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico
Rede Mineira de Engenharia de Tecidos e Terapia Celular
Article History
Received: 2 September 2024
Revised: 19 March 2025
Accepted: 3 April 2025
First Online: 1 July 2025
Competing interests
: BEE is a cofounder of Osmol Therapeutics, a company that is targeting NCS1 for therapeutic purposes.